10

15

CLAIMS

What is claimed is:

- A pregabalin lactose conjugate, or a pharmaceutically acceptable salt, ester, amide, and prodrug thereof.
- 5 2. A compound according to Claim 1 selected from:
 - (S)-1-[3,4-Dihydroxy-6-hydroxymethyl-5-(3,4,5-trihydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2-yl]-4-isobutyl-pyrrolidin-2-one;
 - (S)-4-Isobutyl-1-(2,3,4,5-tetrahydroxy-tetrahydro-pyran-2-ylmethyl)-pyrrolidin-2-one;
 - (S)-1-[2,3-Dihydroxy-5-hydroxymethyl-4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-furan-2-ylmethyl]-4-isobutyl-pyrrolidin-2-one;
 - (S)-4-Isobutyl-1-[2,3,5-trihydroxy-4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2-ylmethyl]-pyrrolidin-2-one; and
 - (S)-4-Isobutyl-1-(2,3,4-trihydroxy-5-hydroxymethyl-tetrahydrofuran-2-ylmethyl)-pyrrolidin-2-one.
 - 3. A compound according to Claim 2 selected from:

5 4. A pharmaceutical formulation comprising at least one compound of
Claim 1 and a pharmaceutically acceptable carrier, excipient, or diluent
thereof.

5

10

15

20

- 5. A method for treating a subject having a central nervous system disorder or disease by administering to the subject a pharmaceutically effective amount of a compound of Claim 1.
- 6. A method according to Claim 5 wherein the central nervous system disorder or disease is depression, seizure, anxiety, pain, sleep disorder, consumptive disorder, psychosis, dyskinesia, Huntington's disease, or Parkinson's disease.
- 7. A method according to Claim 5 wherein the compound is selected from:
 - (S)-1-[3,4-Dihydroxy-6-hydroxymethyl-5-(3,4,5-trihydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2-yl]-4-isobutyl-pyrrolidin-2-one;
 - (S)-4-Isobutyl-1-(2,3,4,5-tetrahydroxy-tetrahydro-pyran-2-ylmethyl)-pyrrolidin-2-one;
 - (S)-1-[2,3-Dihydroxy-5-hydroxymethyl-4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-furan-2-ylmethyl]-4-isobutyl-pyrrolidin-2-one;
 - (S)-4-Isobutyl-1-[2,3,5-trihydroxy-4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2-ylmethyl]-pyrrolidin-2-one; and
 - $(S)\hbox{-}4\hbox{-}Isobutyl\hbox{-}1\hbox{-}(2,3,4\hbox{-}trihydroxy\hbox{-}5\hbox{-}hydroxymethyl\hbox{-}tetrahydrofuran-}2\hbox{-}ylmethyl)\hbox{-}pyrrolidin-}2\hbox{-}one.$